XXth World Congress International Society for Heart Research

Kyoto, Japan

13th-16th May 2010

www.ishr2010.com

Congress Schedule and Symposium List

■ CONGRESS SCHEDULE/SCIENTIFIC PROGRAM

S=SymposiumKRDLA=Keith Reimer Distinguished Lecture AwardJPDLA=Janice Pfeffer Distinguished Lecture AwardPDLA=President’ s Distinguished Lecture AwardOIA=Outstanding Investigator AwardPHDSA=Peter Harris Distinguished Scientist AwardMPP=Moderated Poster PresentationLS=Luncheon Seminar

S=SymposiumRAA=Research Achievement AwardMPP=Moderated Poster PresentationLS=Luncheon Seminar

ISHR2010 ISHR2010 ISHR2010 ISHR2010 ISHR2010 (as of November 20, 2009)

S1. Thrombus and anti-platelet treatment for ischemic heart disease (sponsored by: sanofi-aventis K.K.)

-1 Antiplatelet therapy: up-to-date(T. B. A.)

-2 Epidemiology and therapeutic evidence for atherothrombosisShinya Goto (Tokai University, Japan)

-3 Lipid mediators and atherothrombosisYutaka Yatomi (University of Tokyo, Japan)

-4 Prevention of coronary artery disease and antiplatelet therapyTakaaki Isshiki (Teikyo University, Japan)

S2. Cardio-renal interaction in heart failure (sponsored by: Banyu Pharmaceutical Co., Ltd.)

-1 Role of oxidative stress in cardio-renal interaction in heart failure(T. B. A.)

-2 Mechanisms for the cardio-renal interaction in heart failure(T. B. A.)

-3 Roles of the PlGF/sFLT system in cardio-renal connectionYoshihiko Saito (Nara Medical University, Japan)

-4 Role of Epo/EpoR system in cardio-renal interaction in heart failureYutaka Kagaya (Tohoku University, Japan)

S3. Genetic background of lethal arrhythmia (sponsored by: Eisai Co., Ltd.)

-1 (Keynote lecture) Molecular genetics of progressive cardiac conduction disturbancesJean-Jacques Schott (IRT-UN, France)

-2 Molecular genetics of Brugada syndromeNaomasa Makita (Nagasaki University, Japan)

-3 Molecular genetics of long QT syndromeWataru Shimizu (National Cardiovascular Center, Japan)

-4 Molecular genetics of short QT syndromeHiroshi Watanabe (Niigata University, Japan)

S4. Mitochondria in cell life and death (sponsored by: ISHR International)

-1 Mitochondria dynamicsLuca Scorrano (University of Geneva, Switzerland)

-2 Mitochondria in cell death: from apoptosis to autophagyRoberta A. Gottlieb (San Diego State University, USA)

-3 Autophagy in cardiac proteotoxicityJoseph A. Hill (University of Texas, USA)

-4 Mitochondrial permeability transition and cardiac cell deathFabio Di Lisa (University of Padova, Italy)

S5. Calcium signaling in cardiac dysfunction, cell death and remodelling (sponsored by: ISHR Interna-tional)

-1 Cardiac calcium regulation in health and diseaseDavid Eisner (University of Manchester, UK)

-2 CaMKII signaling in myocardial cell deathAlicia Mattiazzi (Universidad Nacional de La Plata, Argentina)

-3 Calcium sparks and superoxide flashesHeping Cheng (Peking University, China)

-4 Calcium handling and novel pathways for cardioprotectionEvangelia Kranias (University of Cincinnati, USA)

S6. MicroRNAs in cardiovascular development and disease (sponsored by: ISHR International)

-1 MicroRNA regulation of hypoxia adaptationMaha Abdellatif (University of Medicine and Dentistry of New Jersey, USA

-2 MicroRNA control of cardiac development and pathophysiologyGianlugi Condorelli (National Research Council, Italy)

-3 Fibroblasts in cardiac pathogenesis: role of microRNAsStefan Engelhardt (Technische Universitat Muenchen, Germany)

-4 Control of cardiac excitability by microRNAsAhiguo Wang (Harbin Medical University, China)

S7. Signaling survival (sponsored by: ISHR North American Section)

-1 Alpha adrenergic receptor and ERK survival signalingPaul Simpson (University of California-San Francisco, USA)

-2 AMP kinase signaling and cardioprotectionRong Tian (Harvard Medical School, USA)

-3 Beta-arrestin mediated cardioprotectionHoward Rockman (Duke University, USA)

-4 PKC regulation of glucose metabolism and protectionPeipei Ping (University of California-Los Angels, USA)

S8. Myocardial stress: ROS, ischemia and inotropy (co-sponsored by: ISHR Australasian and Latin American Sections)

-1 ROS signalingAlejandro Aiello (UNLP, Argentina)

-2 ROS signaling underlying diabetic cardiomyopathy, and can we counter-act it?Rebecca H. Ritchie (Baker IDI Heart & Diabetes Institute, Australia)

-3 Ischemia-reperfusion and preconditioningDavid A. Saint (University of Adelaide, Australia)

-4 Ischaemia, cardioprotection and ageingJohn P. Headarick (Griffith University Gold Coast, Australia)

S9. Pathophysiology and treatment of diastolic heart failure (sponsored by: Dainippon Sumitomo Pharma Co., Ltd.)

-1 Pathophyiology unclarified yet?: from animals to patientsKazuhiro Yamamoto (Osaka University, Japan)

-2 Clinical characteristics of new entity of the disease: age, gender and comorbidityMiyuki Makaya (Hokkaido University, Japan)

-3 What is a therapeutic strategy: evidence or experience?Katsuya Onishi (Mie University, Japan)

-4 Unsolved issues and future directions of diastolic heart failure(T. B. A.)

S10. Pathophysiology of pulmonary hypertension and right heart failure (sponsored by: Otsuka Pharaceutical Co., Ltd.)

-1 Characteristics of pulmonary artery smooth muscle cells of patients with IPAHKazufumi Nakamura (Okayama University, Japan)

-2 Role of inflammation and bone marrow-derived stem cells in the pathogenesis of pulmonary hypertension: therapeutic potential

Yoshihide Mitani (Mie University, Japan)-3 Challenge to the translational research for the pulmonary arterial hypertension

Masaharu Kataoka (Kyorin University, Japan)-4 (T. B. A)

(T. B. A.)S11. Lipid metabolism and atherosclerosis (sponsored by: Novartis Pharma K.K.)

-1 Novel target for HDL-raising therapy(T. B. A.)

-2 HDL metabolism and CETP inhibitionShizuya Yamashita (Osaka University, Japan)

-3 Dysfunctional HDL and atherosclerosis(T. B. A.)

-4 HDL-targeted therapy and apoA-I mimetic peptidesKeijiro Saku (Fukuoka University, Japan)

S12. Mitochondria in myocardial ischemia and reperfusion (sponsored by: ISHR International)

-1 Molecular identification of a novel mitochondrial ATP-dependent potassium channelBrian O’Rourke (Johns Hopkins University, USA)

-2 Mitochondrial permeability transition in ischemia/reperfusionChirstopher P. Baines (University of Missouri, USA)

-3 Regulation of the mitochondrial permeability transition poreAndrew Halestrap (University of Bristol, UK)

-4 Connexins and mitochondriaRainer Schulz (University of Essen, Germany)

S13. Sodium homeostasis and cardiac function (sponsored by: ISHR International)

-1 Intracellular sodium regulation in cardiac myocytes: an overviewDonald M. Bers (University of California-Davis, USA)

-2 Sodium overload-triggered apoptosis in the failing heartMartin Vila Petroff (Universidad Nacional de La Plata, Argentina)

-3 Sodium dysregulation in failing human myocardiumBurkert Pieske (Medical University of Graz, Austria)

-4 Regulation and functions of the cardiac Na/H exchangerShigeo Wakabayashi (National Cardiovascular Center, Japan)

S14. Genetic mechanisms of myocardial disease (sponsored by: ISHR International)

-1 Genetic causes of human heart failure: an overviewJonathan G. Seidman (Harvard Medical School, USA)

-2 Arrhythmogenic cardiomyopathyXander H. T. Wehrens (Baylor College of Medicine, USA)

-3 Hypertrophic and dilated cardiomyopathyChris Semsarian (University of Sydney, Australia)

-4 Peripartum cardiomyopathyDenise Hilfiker (Hannover Medical School, Germany)

S15. Mechanisms of cardiac electrical and mechanical dysfunction and repair (sponsored by: ISHR North American Section)

-1 Genetic basis of cardiac arrhythmiasBarry London (University of Pittsburgh, USA)

-2 Role of CaMKII in acquired heart failure and arrhythmiasMark Anderson (University of Iowa, USA)

-3 T-type Ca channels and cardiac progenitor cellsSteven Houser (Temple University, USA)

-4 Cardiac cell replacement: missteps and opportunitiesCharles Murry (University of Washington, USA)

S16. Calcium handling and signaling proteins: regulation and dysregulation (co-sponsored by: ISHR Australasian and Latin American Sections)

-1 L-type Ca channel and free radical regulationLivia C. Hool (University of Western Australia, Australia)

-2 CaMKII regulation of Na+/H+ exchanger functionCecilia Mundina-Weilenmann (UNLP, Argentina)

-3 SR luminal regulation of Ca releaseDerek R. Laver (University of Newcastle, Australia)

-4 Calcium handling in failure: position, position, positionMark B. Cannell (University of Auckland, New Zealand)

S17. Vulnerable plaque and aborted rupture (including; RAS) (sponsored by: Chugai Pharmaceutical Co., Ltd.)

-1 Inflammation as a key mediator in plaque formationHiroyuki Daida (Juntendo University, Japan)

-2 ER stress and atherosclerosis(T. B. A.)

-3 Mechanism and pathophysiology of plaque ruptureHiroaki Shimokawa (University of Tokyo, Japan)

-4 ER stress as a key mediator in plaque ruptureMasafumi Myoishi (Tufts Medical Center, USA)

S18. Genetic background in aging (sponsored by: Bristol-Myers Squibb Company)

-1 Estrogen as a key mediator for vascular protectionSuzanne Oparil (University of Alabama at Birmingham, USA)

-2 Metabolic syndrome accelerates vascular aging?Hiroshi Itoh (Keio University, Japan)

-3 Vascular aging and vascular injury: synonymous or analogous?Tohru Minamino (Chiba University, Japan)

-4 Type of stroke dependent on vascular agingMasaki Mogi (Ehime University, Japan)

S19. The race for the implantable cardiomyocyte: who is winning? (sponsored by: ISHR International)

-1 The human embryonic stem cell?Chris Denning (University of Nottingham, UK)

-2 The adult cardiac progenitor cell?Michael Schneider (Imperial College London, UK)

-3 The induced pluripotent cell?Jun K. Yamashita (Kyoto University, Japan)

-4 The mesenchymal stem cell?Muhammad Ashraf (University of Cincinnati, USA)

S20. Cardioprotective interventions in acute ischemia (co-sponsored by: ISHR International/The 15th International Symposium on Adenosine, Cardioprotectionand its Clinical Application)

-1 Remote ischemic preconditioning: from the laboratory to the clinicDerek Hausenloy (University College London, UK)

-2 Postconditioning: mechanisms and clinical applicationMichel Ovize (University of Lyon, France)

-3 Acidic reperfusion to preserve myocardial viabilityDavid Garcia-Dorado (Hospital Universitari Vall d’Hebron, Spain)

-4 Harnessing the protective potential of the ER stress responseChristoper Glembotski (San Diego State University, USA)

S21. Toll-like receptors, heat shock, inflammation and the heart (sponsored by: ISHR International)

-1 Toll-like receptors in cardiac injuryWei Chao (Harvard Medical School, USA)

-2 Extracellular HSP60 and cardiac myocyte apoptosisAnne A. Knowlton (University of California-Davis, USA)

-3 Alpha-B crystallopathy in the heartAtsushi Sanbe (National Research Institute of Child Health and Development, Japan)

-4 Heat shock proteins and inflammationR. William Currie (Dalhousie University, Canada)

S22. Sarcomeric signals in health and cardiac disease (sponsored by: ISHR International)

-1 Mechanisms of muscle degeneration, regeneration and repairMarco Sandri (University of Padova, Italy)

-2 Muscle Lim Protein in cardiac disease: the sarcomere and beyondChristian Geier (Charité Universitätsmedizin Berlin, Germany)

-3 Molecular etiology of idiopathic cardiomyopathyAkinori Kimura (Tokyo Medical and Dental University, Japan)

-4 The sarcomeric M-band in strain sensing and cardiac diseaseMathias Gautel (King’s College London, UK)

S23. Influence of major cardiovascular risk factors on cardioprotective mechanisms (sponsored by: ISHR European Section)

-1 Loss of protection by ischemic pre-and postconditioning with agingGerd Heusch (University of Essen, Germany)

-2 Effect of aging and hypercholesterolemia on cardioprotectionRoberto Bolli (University of Louisville, USA)

-3 Cardioprotection in aging and diabetic cohortsKarin Przyklenk (Wayne State University, USA)

-4 Influence of hyperlipidemia and metabolic diseases on cardioprotective mechanisms and gene expression

Peter Ferdinandy (University of Szeged, Hungary)S24. New strategies for stem cell therapy and vascular generation (sponsored by: ISHR Japanese Section)

-1 Redox signaling in stem cell homingDipak K. Das (University of Connecticut, USA)

-2 The role of the innate immune system in the development of a collateral circulationWolgang Schaper (Heart and Lung Institute Max-Plank-Society, Germany)

-3 Future prospect of heart regeneration using human iPS cellsKeiichi Fukuda (Keio University, Japan)

-4 Stem cell therapy for severe heart failure(T. B. A.)

S25. RAAS activation and remodeling of the failing heart (sponsored by: Astellas Pharma Inc.)

-1 Renin inhibitoris a new strategy for treatment of hypertension and heart failure?Henry Krum (Monash Centre of Cardiovascular Research and Education in Therapeutics, Australia)

-2 Is ACE inhibitor a best choice for treatment of chronic heart failure?Atsuhisa Sato (IUHW Mita Hospital, Japan)

-3 Which is a better choice?: ACE inhibitor or ARBShin-ichiro Miura (Fukuoka University, Japan)

-4 Is aldosterone antagonist a unique agent for treatment of hypertension and heart failure?Michihiro Yoshimura (Jikei University, Japan)

S26. Vascular endothelial function and cardiovascular events (co-sponsored by: Mitsubishi Tanabe Pharma Corporation)

-1 Coronary endothelial function and cardiovascular events(T. B. A.)

-2 Importance of endothelial function in the coronary and peripheral circulation(T. B. A.)

-3 Lessons from genetically engineered mice lacking all NO synthasesMasato Tsutsui (University of Ryukyus, Japan)

-4 Novel findings with the NO-sensing catheter in animals and humansMasami Goto (Kawasaki University of Medical Welfare, Japan)

S27. Stem cell fate determination (Kaito Symposium in Memory of Yoshio Ito (ISHR President 1989-92))

-1 A novel cardiomyocyte differentiation factorIssei Komuro (Chiba University/Osaka University, Japan)

-2 Manipulating stem cell homing and engrafment for cardiac repairJianyi (Jay) Zhang (University of Minnesota, USA)

-3 Cardiac differentiation potential of iPS versus ES cellsTimothy J. Kamp (University of Wisconsin, USA)

-4 Heart regeneration in zebra fishKenneth Poss (Duke University, USA)

S28. Emerging therapeutic approaches in ischemic heart disease (co-sponsored by: ISHR International/The 15th International Symposium on Adenosine, Cardioprotectionand its Clinical Application)

-1 Targeting autophagy and apoptosis in ischaemic cardimyopathyLorrie Kirshenbaum (University of Manitoba, Canada)

-2 Therapeutic manipulation of peptide hormonesGary Baxter (Cardiff University, UK)

-3 Glycogen synthase kinase 3 inhibition as a cardioprotective approachCharles Steenbergen (The Johns Hopkins University, USA)

-4 Redox signaling in cardioprotectionJames Downey (University of South Alabama, USA)

S29. Novel protein signaling mechanisms in the heart (sponsored by: ISHR International)

-1 Aldehyde dehydrogenase and ischemic stressDaria Mochly-Rosen (Stanford University, USA)

-2 RhoA activation: mechanisms and significanceThomas Wieland (University of Heidelberg, Germany)

-3 Protein kinase D regulation of cardiac function and remodelingMetin Avkiran (King’s College London, UK)

-4 Multifunctional roles of cardiac p90 RSKsJun-ichi Abe (University of Rochester, USA)

S30. Modulation of myocardial contraction by modification of sarcomeric proteins (sponsored by: ISHR North American Section)

-1 AKAP's in protein kinase A signalingMeredith Bond (University of Maryland, USA)

-2 Regulation of contraction kinetics by sarcomere protein phosphorylationRichard Moss (University of Washington, USA)

-3 Familial hypertrophic cardiomyopathies due to mutations in TnTJil Tardiff (Albert Einstein College of Medicine, USA)

-4 Molecular basis for dysfunction in heart failureJennifer Van Eyk (Johns Hopkins University, USA)

S31. Animal models of hypertrophy and failure: what have we learned? (sponsored by: ISHR Australasian Section)

-1 Autophagy, angiotensin II and failureLea M. D. Delbridge (University of Melbourne, Australia)

-2 Inflammation and signaling in pre-failing heartsXiao-Jun Du (Baker IDI Heart & Diabetes Institute, Australia)

-3 PI3K-induced physiological hypertrophy protects against heart failureJulie R. McMullen (Baker IDI Heart & Diabetes Institute, Australia)

-4 Sensors and regulators of cardiac metabolism in adaptation and failureSalvatore Pepe (Royal Children’s Hospital, Australia)

S32. Metabolic syndrome and PPAR signaling (sponsored by: Takeda Pharmaceutical Co., Ltd.)

-1 Pathogenesis of insulin resistance and type 2 diabetes(T. B. A.)

-2 Diabetes and vascular calcificationMasahiko Kurabayashi (Gunma University, Japan)

-3 The role of AGE in atherosclerosisHiroshi Yamamoto (Kanazawa University, Japan)

-4 Effects of statin on endothelial dysfunction in diabetesAtsunori Kashiwagi (Shiga University of Medical Science, Japan)

S33. Mechanistic insight for better management of hypertension (sponsored by: Bayer AG)

-1 The genetic approach in management of hypertensionRutai Hui (Fu Wai Hospital, China)

-2 Endothelial dysfunction in hypertension: mechanistic aspect and therapeutic strategyShinichiro Ueda (University of Ryukyus, Japan)

-3 The role of RAS in hypertensionHiromi Rakugi (Osaka University, Japan)

-4 Gender difference in management of hypertension(T. B. A.)

S34. Use of stem cells to repair infarcted myocardium (sponsored by: ISHR International)

-1 The microvasculature as a therapeutic target in ischemic diseaseDouglas Losordo (Northwestern University, USA)

-2 Cardiosphere-derived cells for therapeutic useEduardo Marbán (Cedars-Sinai Heart Institute, USA)

-3 Use of stem cells to repair infarcted myocardiumRoberto Bolli (University of Louisville, USA)

-4 Use of stem cells for congestive heart failureStefan P. Janssens (University of Leuven, Belgium)

S35. Novel effectors and modulators in cardiac hypertrophy and failure (Bayer Yakuhin Symposium in Memory of Howard E. Morgan (ISHR President 1983-86))

-1 CaMKII in heart failure development: guilty as chargedJoan Heller Brown (University of California-San Diego, USA)

-2 Pim-1 kinase in cardiac hypertrophy and failureMark Sussman (San Diego State University, USA)

-3 Cell death pathways in the transition to heart failureRui-ping Xiao (NIH, USA)

-4 Autophagy as an adaptive mechanism to cardiac stressKinya Otsu (Osaka University, Japan)

S36. Nitric oxide signaling in the cardiovascular system (sponsored by: ISHR International)

-1 Nitric oxide signaling: an overviewJean-Luc Balligand (University of Leuven, Belgium)

-2 Mice lacking nitric oxide synthase: what have we learned?Barbara Casadei (University of Oxford, UK)

-3 Nitric oxide signaling by S-nitrosylationElizabeth Murphy (NIH, USA)

-4 New insights into nitric oxide signaling in manAjay M. Shah (King’s College London, UK)

S37. Post-translational modification of cardiac sarcomeric proteins (sponsored by: ISHR International)

-1 Regulation of cardiac function by sarcomeric protein phosphorylationR. John Solaro (University of Illinois at Chicago, USA)

-2 Mechanisms and significance of cardiac MyBP-C phosphorylationSakthivel Sadayappan (Loyola University Chicago, USA)

-3 Novel signaling pathways in sarcomeric protein phosphorylationFriederike Cuello (King’s College London, UK)

-4 Sarcomeric protein degradation and cardiac dysfunctionLucie Carrier (University Medical Center Hamburg-Eppendorf, Germany)

S38. Eicosanoids and vascular function (sponsored by: ISHR European Section)

-1 COXes in the vascular wallJane Mitchell (Imperial College London, UK)

-2 Transcriptional regulation of thrombin receptors in human vascular smooth muscle cells by vasodilatory prostaglandins

Karsten Schrör (Heinrich-Heine-Universität Düsseldorf, Germany)-3 Vascular eicosanoid nuclear signaling pathways

David Bishop-Bailey (Queen Mary University of London, UK)-4 Cytochrome P-450 metabolites in vasoregulation

Ingrid Fleming (Goethe-University, Germany)S39. Novel approaches for treatment of heart failure (sponsored by: Daiichi Sankyo Co., Ltd.)

-1 New approaches for cardiac stem cell therapy for myocardial infarction and heart failureEduardo Marbán (Cedars-Sinai Heart Institute, USA)

-2 Application of iPS cells for treatment of advanced cardiac failureYoshiki Sawa (Osaka University, Japan)

-3 Nobel application of cardiomyocyte differentiation factor for treatment of heart failureIchiro Shiojima (Osaka University, Japan)

-4 Statin as a potential drug for treatment of heart failureKoichi Node (Saga University, Japan)

S40. Novel insights in adipocytokins and cardiovascular disease (sponsored by: Takeda Pharmaceutical Co., Ltd.)

-1 Regulation of metabolism by myokinesKenneth Walsh (Boston University, USA )

-2 The molecular mechanism of adiponectin and its receptors in protection from cardio metabolic syndromeTakashi Kadowaki (University of Tokyo, Japan)

-3 Is adiponectin a key player in cardiovascular disease?Tohru Funahashi (Osaka University, Japan)

-4 Vascular regeneration by adipocytokinesToyoaki Murohara (Nagoya University, Japan)

S41. Tissue engineering for the heart (sponsored by: ISHR International)

-1 Embryonic stem cell-derived cardiomyocytes for a cardiac patchSian Harding (Imperial College London, UK)

-2 In vivo tissue-engineered heart valveKeiichi Kanda (Kyoto Prefectural University of Medicine, Japan)

-3 Cell sheet approach for cardiac repairTatsuya Shimizu (Tokyo Women’s Medical University, Japan)

-4 Hydrogel approach for cardiac repairThomas Eschenhagen (University Medical Center Hamburg-Eppendorf, Germany)

S42. Protein processing and quality control (sponsored by: ISHR International)

-1 Protein quality control and cardiac dysfunctionJeffrey Robbins (Cincinnati Children’s Hospital, USA)

-2 Ubiquitin ligases and cardiac functionCam Patterson (University of North Carolina at Chapel Hill, USA)

-3 ER stress and cardiovascular remodelingTetsuo Minamino (Osaka University, Japan)

-4 Intracellular aggregation in proteinopathiesDavid Rubinsztein (University of Cambridge, UK)

S43. p38 MAPK inhibition in myocardial infarction and remodelling: beside the bedside? (sponsored by: ISHR International)

-1 p38 MAPK signaling in the heartYibin Wang (University of California-Los Angeles, USA)

-2 p38 MAPK inhibition and cardiac remodellingHenry Krum (Monash University, Australia)

-3 A chemical genetic approach to determine p38 function in acute MIMichael Marber (King’s College London, UK)

-4 Design of clinical trials of p38 inhibition in acute coronary syndromesDennis L. Sprecher (Glaxo Smith Kline, USA)

S44. Protection from cardiac injury (sponsored by: ISHR Japanese Section)

-1 Molecular mechanisms of Ca overload in cardiac injury(T. B. A.)

-2 Ca overload and Ca injury: ryanodine receptor regulation(T. B. A.)

-3 Glycogen synthase kinase (GSK-3beta) as a therapeutic target for cardiomyocyte protection(T. B. A.)

-4 Cardioprotective proteins mediating ischemic preconditioningKen Shinmura (Keio University, Japan)

S45. Mechano-transduction and vascular biology (sponsored by: ISHR Chinese Section)

-1 Flow-induced AMPK activation and vascular homeostasisJohn Shyy (University of California-Riverside, USA)

-2 Shear stress and endothelial activationYi Zhu (Peking University, China)

-3 Biomechanical force-induced differentiation of ES cells into vascular cellsJoji Ando (Dokkyo Medical University, Japan)

-4 miRNA regulation by mechanical force in vascular endothelial cellsNanping Wang (Peking University, China)

S46. Novel anticoagulant treatment for atrial fibrillation (sponsored by: Nippon Boehringer Ingelheim Co., Ltd.)

-1 (Keynote lecture) Novel anticoagulant therapy: inhibition of thrombin/Xa factor(T. B. A.)

-2 Current status for anticoagulant treatment in AF patientsYukihiro Koretsune (Osaka National Hospital, Japan)

-3 New strategies for prevention of AF-induced cardiovascular eventsKen Okumura (Hirosaki University, Japan)

-4 Warfarin: still keep a standard therapy for AF patiens?Hirotsugu Atarashi (Nippon Medical School, Japan)

S47. Molecular mechanisms of myocarditis and heart failure (sponsored by: Siemens Medical Solutions Diagnostics K.K.)

-1 Heart failure related to viral infectionKirk U. Knowlton (University of California-San Diego, USA)

-2 Dendritic cells for the pathogenesis of heart failureHideo Yasukawa (Kurume University, Japan)

-3 Autoimmune myocarditis and its mechanismHaruo Hanawa (Niigata University, Japan)

-4 Gene modulation for the treatment of myocarditisJun-ichi Suzuki (University of Tokyo, Japan)

S48. Vascular injury, repair and regeneration (Canon Symposium in Memory of Normal R. Alpert (JMCC Editor 1993-98))

-1 Neurotrophins control on angiogenesis and vasculogenesisCostanza Emanueli (University of Bristol, UK)

-2 Vascular and stromal cell activation as a pathogenic pathwayRyozo Nagai (University of Tokyo, Japan)

-3 Therapeutic potential of thymosin beta4 for angiogenesisNicola Smart (University College London, UK)

-4 VEGFs for more vessels and muscleKari Alitalo (University of Helsinki, Finland)

S49. Mechanisms of redox signaling (sponsored by: ISHR International)

-1 Protein S-guanylation: a new post-translational regulatory modificationTakaaki Akaike (Kumamoto University, Japan)

-2 Redox regulation of soluble guanylyl cyclase by S-nitrosylationAnnie Beuve (University of Medicine and Dentistry of New Jersey, USA)

-3 Consequences of SERCA oxidation in the cardiovascular systemRichard A. Cohen (Boston University, USA)

-4 Redox regulation of protein kinases A and GPhilip Eaton (King’s College London, UK)

S50. Cancer versus heart disease: can we cure both? (sponsored by: ISHR International)

-1 Therapeutic angiogenesis in cardiovascular diseasePaolo Madeddu (University of Bristol, UK)

-2 Inhibition of angiogenesis in cancer therapyMasahiro Inoue (Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan)

-3 Drug safety issues for tyrosine kinase inhibitors in oncologyVito Sasseville (Bristol-Myers Squibb, USA)

-4 Heart failure and tyrosine kinase inhibitorsThomas Force (Thomas Jefferson University, USA)